Bristol Myers Squibb Co 8-K, filed Feb 2, 2021
Bristol Myers Squibb Co (BMY)
8-K
2021-02-02
For: 2021-02-02
View Original
Added on
April 02, 2026
About this 8-K
Bristol Myers Squibb Co filed this 8-K on February 2, 2021.
Items reported
- Item 1.02: Ended a material agreement
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 2, 2021
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction of incorporation or organization)
|
(Commission File Number)
|
(I.R.S Employer Identification No.)
|
, 14th Floor
(Address of principal executive offices) (zip code)
Registrant’s telephone number, including area code: (212 ) 546-4000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 1.02
|
Termination of a Material Definitive Agreement.
|
As previously reported, on November 4, 2020 Bristol-Myers Squibb Company (“Bristol Myers Squibb”) entered into a Term Loan Credit Agreement (the “Term Loan
Agreement”) with the lenders party thereto and Citibank, N.A., as administrative agent. On February 2, 2021, Bristol Myers Squibb prepaid in full all fees under the Term Loan Credit Agreement and terminated all commitments thereunder. No borrowings
were ever made under the Term Loan Credit Agreement.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
BRISTOL-MYERS SQUIBB COMPANY
|
||||
|
Dated: February 2, 2021
|
By:
|
/s/ Katherine R. Kelly
|
||
|
Name:
|
Katherine R. Kelly
|
|||
|
Title:
|
Corporate Secretary
|
|||